CancerNetwork®’s Week in Review: June 21, 2021
Here are some of the important updates from last week you might have missed, including data from the 2021 ASCO Annual Meeting.
Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology news.
This week’s featured content comes from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, prostate cancer, and a pair of articles focusing on breast cancer.
Extended ARAMIS Trial Follow-Up Shows Prolonged Tolerability of Darolutamide in nmCRPC
Almost all patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated on the phase 3 ARAMIS trial (NCT02200614) were able to receive the full planned dose of darolutamide (Nubeqa) for their disease.
ARAMIS was a double-blind, randomized phase 3 trial of darolutamide in men with nmCRPC to examine the potential of second-generation androgen receptor inhibitors, which could prolong metastasis-free survival with minimal adverse events. The trial was unblinded at primary analysis, after which all patients could receive open-label darolutamide.
In recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.
Novel agents, such as HIF2α inhibitors, are currently being studied as single agents and in combination with other treatment modalities in efforts to improve patient outcomes in mRCC.
Approximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years.
In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.
Lenalidomide Plus Rituximab Continues to Improve PFS With Manageable Safety in Lymphoma Subtypes
The addition of lenalidomide (Revlimid) to rituximab (Rituxan) continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas (iNHL) and mantle cell lymphomas (MCLs).
In the retrospective review of the single-center, prospective, open-label phase 2 trial(NCT00783367), investigators aimed to evaluate 5- and 10-year outcomes for patients with iNHL and MCL with rituximab resistance who were treated with lenalidomide and rituximab to identify adverse events that led to dose discontinuation.
Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status.
Investigators launched the trial to assess the possible association of locoregional treatment with survival in a large, population-based study. In addition to examining the efficacy of breast-conserving surgery plus radiotherapy, investigators assessed the association of socioeconomic factors and comorbidities with overall survival and breast-cancer specific survival.
For more updates from CancerNetwork®, make sure to follow us on Facebook, Twitter, and LinkedIn to stay up to date on the latest in oncology.
